Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Kuhlen, M; Bader, P; Sauer, M; Albert, MH; Gruhn, B; Güngör, T; Kropshofer, G; Lang, P; Lawitschka, A; Metzler, M; Pentek, F; Rossig, C; Schlegel, PG; Schrappe, M; Schrum, J; Schulz, A; Schwinger, W; von Stackelberg, A; Strahm, B; Suttorp, M; Luettichau, IT; Wößmann, W; Borkhardt, A; Meisel, R; Poetschger, U; Glogova, E; Peters, C.
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial.
BRIT J HAEMATOL. 2018; 183(1): 104-109.
Doi: 10.1111/bjh.15511
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Schwinger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Osteonecrosis (ON) was prospectively assessed in 557 children and adolescents in the Berlin-Frankfurt-Münster Stem Cell Transplantation in children with acute lymphoblastic leukaemia 2003 trial. Median age at haematopoietic stem cell transplantation (HSCT) was 10·3 years (range 0·5-26). Cumulative incidence of symptomatic ON (sON) was 9% at 5 years (standard deviation 1%), median time from HSCT to diagnosis of sON was 12·4 months (range 1-126). Multivariate analysis identified age at HSCT [10-15 years vs. <10 years: hazard ratio (HR) 3·73, P = 0·009; >15 years vs. <10 years: HR 5·46, P = 0·001], diagnosis of sON prior to HSCT and chronic graft-versus-host disease (yes versus no: HR 2·696, P = 0·015) as significant independent risk factors for the development of sON.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.
- Find related publications in this database (Keywords)
-
osteonecrosis
-
children
-
haematopoietic stem cell transplantation
-
ALL